Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

ST PETER PORT, Guernsey and LONDON, July 6 /PRNewswire/ --

- GBP13.1 Million Funding to Drive Novel Antibiotics Platform Addressing Areas of Major Unmet Need, Including Hospital Acquired Infections C. Difficile and MRSA

Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP ("CP2"), today announces its investment in a majority shareholding in Novacta Biosystems Limited ("Novacta"), which is developing a portfolio of antibiotics. The total being raised is GBP13.1m ($21.6m), payable against pre-agreed milestones. As part of this investment certain existing investors are re-investing.

Novacta is a UK-based company developing novel, naturally-derived products known as 'lantibiotics' as potential drugs. Lantibiotics have potent anti-infective properties but have historically been underexploited owing to a lack of research tools, a challenge that Novacta has successfully addressed through its proprietary technology platform. The most advanced programme will enter the clinic next year to treat infections caused by Clostridium difficile ("C. difficile"). The Wellcome Trust has provided in the order of GBP4m of translational funding to Novacta since 2004 for the development of the platform technology and more recently the C. difficile programme.

New anti-infective drugs are needed to target C. difficile without depleting other beneficial bacteria in the gut and preclinical data show that Novacta's lead lantibiotics selectively kill C. difficile with less disturbance of normal gut bacteria than seen with existing drugs. C. difficile infections (CDIs) are a serious problem: the number of cases grew by 22 percent in the UK last year, accounting for twice as many deaths as MRSA.

Novacta's pipeline also includes programmes targeting other areas of unmet medical need in bacterial infection. These include novel prom
'/>"/>

SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... York (PRWEB) August 29, 2014 According to ... Orthobiologics Market” the global orthobiologics market was valued at USD ... market worth USD 5,519.9million in 2019at a CAGR of 5.9% ... aged 50 years and above is afflicted by bone and ... by the year 2020. This has and will continue to ...
(Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
(Date:8/29/2014)... Three Lawrence Livermore researchers have ... Production R&D Award for their research in ... sunlight. , Shared with collaborators from the National ... Nevada, Las Vegas (UNLV), the award recognizes the ... solar-hydrogen production and corrosion processes. , These models ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... BIG SP, Company or Biosensors), today announced that ... for its,BioMatrix(R) drug-eluting stent system, enabling commercialization of ... in Asia and Latin America,that recognize the CE ... the Company, consists of a unique drug-eluting,stent that ...
... Calif., Jan. 17 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... meetings including yearend business review, planning for ... in,Xiaotangshan, Beijing on January 11, 2008., ... from Kiwa,s corporate,headquarters in Beijing, and department ...
... formed Advisory Board to advise on cancer screening methods ... mitochondrial DNA-based disease ... (OTC,Bulletin Board: TBIO) today announced that it has formed ... latest developments and,scientific opportunities in cancer detection screening and ...
Cached Biology Technology:Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 2Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 3Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System 4Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 2Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 3Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3
(Date:8/28/2014)... method for delivering compounds that could positively ... AIDS may be possible, thanks to researchers ... A semi-soft vaginal suppository made from the ... the antiviral drug Tenofovir provides a woman-initiated, ... spread of sexually transmitted infections during unprotected ...
(Date:8/28/2014)... for measuring and imaging how quickly blood flows in ... how drug abuse affects the brain, which may aid ... to better treatment options for recovering drug addicts. The ... Stony Brook University in New York, USA and the ... The Optical Society,s (OSA) open-access journal Biomedical ...
(Date:8/28/2014)... German . Cars, ... help of sophisticated assembly lines. Mobile assembly carriers, on to ... these assembly lines. In the case of a car body, ... in a precise spatial and chronological sequence, resulting in a ... creation of such an assembly line at molecular level has ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Nanoscale assembly line 2Nanoscale assembly line 3
... has discovered that aggressive melanoma cells secrete Nodal, ... formation. , An article describing this research ... of the journal Nature Medicine. The researchers identified the ... injecting aggressive melanoma cells into developing zebrafish embryos, ...
... known more for conflict than conservation, a joint effort ... Society (WCS) and funded by the United States Agency ... the region's unique wildlife and develop the country's first ... is an important and exciting moment for Afghanistan, which ...
... Methylphenidate (Ritalin) elevates norepinephrine levels in the brains ... nerve signal transmissions in the sensory pathways to ... a Philadelphia research team has found. , Their ... how a stimulant aids people with attention deficit ...
Cached Biology News:Malignant melanoma cells secrete protein required for embryo formation 2Afghanistan to protect wildlife and wild lands 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 3